Thrombin Inhibitors: Discovery and Design
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (20 December 2015) | Viewed by 17088
Special Issue Editor
Special Issue Information
Dear Colleagues,
Playing a myriad of procoagulant and anticoagulant roles, thrombin is a central effector in haemostasis and a focal point for blood clotting control, including therapeutic intervention. Given its significant structural similarity to many other serine proteinases carrying out a multitude of disparate tasks, controlling thrombin's behavior with small chemical compounds without interfering with the activity of related enzymes is a formidable challenge. There are, however, many examples of extremely potent and specific thrombin-targeting molecules, namely in the form of natural anticoagulants from haematophagous organisms or from other biological sources. Over the years, many of the unique thrombin recognition and inhibition strategies displayed by these molecules have been unveiled, all while many other synthetic inhibitors have been conceived, developed and perfected. As our knowledge mounts, every new generation of direct thrombin inhibitors brings us closer to the ultimate goal of safely and efficiently modulate thrombin’s activity in a clinical setting. This Special Issue is set to bring together the leading researchers in the fields of discovery and design of specific thrombin inhibitors, helping to disseminate the latest research results and serving as a hub for the establishment of novel and fruitful interactions and collaborations. Original research papers dealing with the discovery, design, characterization, and synthesis of specific thrombin inhibitors are welcome.
Dr. Pedro J. B. Pereira
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Anticoagulant
- Inhibitor
- thrombin inhibition
- serine proteinase
- structure-guided drug design
- structure-function relationships
- drug discovery
- haemostasis
- blood clotting
- macromolecular recognition
- macromolecular interactions
